Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says

MT Newswires Live06-22 23:37

Revolution Medicines' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.

The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.

UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.

Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.

UBS has a buy rating on the stock and a $175 price target.

Price: 163.98, Change: +0.99, Percent Change: +0.61

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645076335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645076335","market":"sh","top_or_hot":-1,"title":"Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a>' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.</p><p>The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.</p><p>UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.</p><p>Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.</p><p>UBS has a buy rating on the stock and a $175 price target.</p><p>Price: 163.98, Change: +0.99, Percent Change: +0.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 23:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a>' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.</p><p>The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.</p><p>UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.</p><p>Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.</p><p>UBS has a buy rating on the stock and a $175 price target.</p><p>Price: 163.98, Change: +0.99, Percent Change: +0.61</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645076335","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645076335","pubTimestamp":1782142633,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Revolution Medicines'  pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.UBS has a buy rating on the stock and a $175 price target.Price: 163.98, Change: +0.99, Percent Change: +0.61","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"瑞银表示，由于双重数据积极，Revolution Medicines的PDAC收入可能增长高达40%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.5},"content_text":"Revolution Medicines' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.UBS has a buy rating on the stock and a $175 price target.Price: 163.98, Change: +0.99, Percent Change: +0.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645076335","isCrawlerRequest":true}